Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...